Having trouble accessing articles? Reset your cache.

Brii expands in infectious via deals with Vir, VBI, WuXi Biologics

Brii Biosciences (Shanghai, China) is broadening its pipeline in HBV and other infectious diseases through a series of new and expanded deals announced Dec. 6, even as CEO Zhi Hong said the company is looking to expand into another therapeutic area.

Brii launched in May with $260 million and three initial partnerships to bring

Read the full 531 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers